This study is a prospective, open label study which is divided into 3 parts.~Part A will be dose escalation segment to identify the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of EBC-129 monotherapy.~Part B will be dose escalation segment to identify the MTD and RP2D of EBC-129 in combination with pembrolizumab.~Part C (dose expansion cohort) will be performed in an expanded cohort of subjects with advanced solid malignancies at the RP2D of EBC-129 as a monotherapy identified in the dose escalation segment, Part A.
This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours